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ARTICLE
Evidence That Translation Reinitiation Leads to a Partially
Functional Menkes Protein Containing Two Copper-Binding Sites
Marianne Paulsen, Connie Lund, Zarqa Akram, Jakob R. Winther, Nina Horn, and
Lisbeth Birk Møller
Menkes disease (MD) is an X-linked recessive disorder of copper metabolism. It is caused by mutations in the ATP7A
gene encoding a copper-translocating P-type ATPase, which contains six N-terminal copper-binding sites (CBS1–CBS6).
Most patients die in early childhood. We investigated the functional effect of a large frameshift deletion in ATP7A
(including exons 3 and 4) identiﬁed in a patient with MD with unexpectedly mild symptoms and long survival. The
mutated transcript, ATP7ADex3+ex4, contains a premature termination codon after 46 codons. Although such transcripts are
generally degraded by nonsense-mediated mRNA decay (NMD), it was established by real-time PCR quantiﬁcation that
the ATP7ADex3+ex4 transcript was protected fromdegradation. A combination of in vitro translation, recombinantexpression,
and immunocytochemical analysis provided evidence that the ATP7ADex3+ex4 transcript was protected from degradation
because of reinitiation of protein translation. Our ﬁndings suggest that reinitiation takes place at two downstream internal
codons. The putative N-terminally truncated proteins contain only CBS5 and CBS6. Cellular localization and copper-
dependent trafﬁcking of the major part of endogenous and recombinant ATP7ADex3+ex4 proteins were similar to the wild-
type ATP7A protein. Furthermore, the ATP7ADex3+ex4 cDNA was able to rescue a yeast strain lacking the homologous gene,
CCC2. In summary, we propose that reinitiation of the NMD-resistant ATP7ADex3+ex4 transcript leads to the synthesis of
N-terminally truncated and at-least-partially functional Menkes proteins missing CBS1–CBS4. This ﬁnding—that a mu-
tation that would have been assumed to be null is not—highlights the need to examine the biochemical phenotype of
patients to deduce the efﬁcacy of copper therapy.
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Menkes disease (MD [MIM 309400]) is an X-linked, mul-
tisystemic lethal disorder of impaired copper metabolism1
caused by mutations in ATP7A (MIM 300011). ATP7A con-
tains 23 exons and encodes a P-type ATPase of 1,500 aa
(EC 3.6.1.36). The ATP7A protein (GenBank accession
number NP_000043) is a member of the CPx-type trans-
membrane ATPase family that performs ATP-driven trans-
location of metal cations across cellular membranes.2 The
characteristic features of MD are due to reduced activity
of copper-requiring enzymes. Classic MD is characterized
by developmental delay, progressive mental retardation,
vascular abnormalities, skeletal changes, loose joints, and
early death (!3 years of age). However, MD shows clinical
heterogeneity, as demonstrated by a variation in progres-
sion and severity of neurological symptoms and age of
death. The mildest form, occipital horn syndrome (OHS),
is primarily characterized by pronounced connective tis-
sue symptoms (reviewed in Horn and Tu¨mer3).
MD is closely related to Wilson disease (WD [MIM
277900]), an autosomal recessive disorder characterizedby
accumulation of copper in the liver, brain, and kidneys
and associated with hepatic cirrhosis and neuronal de-
generation.4,5 WD is caused by mutations in ATP7B (MIM
606882), which encodes another copper-transporting
ATPase, ATP7B, that is highly homologous to ATP7A.6
ATP7A is expressed in most nonhepatic tissues,7 whereas
ATP7B is expressed predominantly in liver.8
Unique for the Menkes and Wilson ATPases is the pres-
ence of six copper-binding sites (CBSs) in the N-terminal
region of the proteins. Each CBS consists of the signature
sequence of heavy metal–binding proteins, GMXCXXC,
with which one copper atom is coordinated via the two
cysteine residues. The ATPases receive copper ions via the
small cytosolic chaperone Atox1.9–12 ATP7A and ATP7B are
normally localized in the trans-Golgi network (TGN),
where they transport copper to copper-requiring enzymes
synthesized within the secretory compartments. In the
presence of elevated copper concentrations, the ATP7A
protein trafﬁcs to cytosolic vesicular compartments and
to the plasma membrane, where it mediates copper
efﬂux,13,14 whereas ATP7B in hepatocytes moves to peri-
canalicular vesicles.15
The role of the CBSs in copper transport has been in-
vestigated by in vitro experiments with isolated mem-
brane vesicles from Chinese hamster ovary (CHO) cells,
expressing ATP7A constructs with different mutations in
the CBSs. It was shown that a protein with no intact CBSs
retained at least 55% copper-transporting activity, indi-
cating that the CBSs are not essential for copper-trans-
porting activity of the Menkes protein.16 In contrast, how-
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Table 1. Primers Used in This Study
Primer Name Sequence (5′–3′ Direction) Remarks
T7-134-(-111) TAATACGACTCACTATAGGGAGAGCTACTGTGACTTCTCCGATTGT In exon 1
T7-M1 TAATACGACTCACTATAGGGAGATGGATCCAAGTATGGGTGTGAAT In exon 2
T7-M461 TAATACGACTCACTATAGGGAGATGCCGCTTTTGACTTCAACTAAT In exon 5
T7-kozak-M461 TAATACGACTCACTATAGGGAGACCACCATGCCGCTTTTGACTTCAACTAAT In exon 5
T7-kozak-M475 TAATACGACTCACTATAGGGAGACCACCATGACACCAGTTCAAGAC In exon 5
CATP7A642 GATCTAAGTGACTTGCTGACCGATCCTTC In exon 8
ATP7Aex1U CGCTAGCTACTGTGACTTCTCCGATTGT In exon 1
ATP7Aex1 AACCATAGGATAGAGAAACC In exon 1
ATP7Aex6L TGGGGGTTGTATAACAGCAGGAT In exon 6
ATP7Aex9L AGACAATCCTGGAAGAATCTGGCGC In exon 9
ATP7Aex21 AGGATTCGGATAAATTTTGTCTTTGCTCTA In exon 21
ATP7Aex22 GCAAAACCAAACCAATGGGCATA In exon 22
ATP7A21/22probe CATAGCTGCTGGAGTTTT Probe (TaqMan)
Nhe-ATP7AUTR CTGCACTAGCAAGCTAGCGGCCGCTCTAGAGAAACCAGGAATGTAA In 5′ UTR; contains NheI site
Nhe-M461 CTGCACTAGCAAGCTAGCACCACCATGCCGCTTTTGACTTCAAC With NheI site and kozak
NheI-M475 CTGCACTAGCAAGCTAGCACCACCATGACACCAGTTCAAGACAA Contains NheI site
Nhe-M461-M475L TGCACTAGCAAGCTAGCACCACCATGCCGCTTTTGACTTCAACTAATGAATTTTATACTAAAGGGCTGACAC Contains NheI site
Yeast-M1 CTGCACTAGCAAGCTAGCAAAAAAAAAAATGGATCCAAGTATGGGTGT Contains NheI site
Yeast-M461 CTGCACTAGCAAGCTAGCAAAAAAAAAAATGCCGCTTTTGACTTCAAC Contains NheI site
Yeast-M475 CTGCACTAGCAAGCTAGCAAAAAAAAAAATGACACCAGTTCAAGACAA Contains NheI site
Yeast-M461-M475L CTGCACTAGCAAGCTAGCAAAAAAAAAAATGCCGCTTTTGACTTCAACTAATGAATTTTATACTAAAGGGCTGACAC Contains NheI site
ever, it was found that CBS5 and CBS6 were necessary and
sufﬁcient for copper-induced trafﬁcking.17
Transcripts with mutations that lead to premature ter-
mination codons (PTC) 150–55 nt upstream from the last
exon, are normally degraded by a mechanism called non-
sense-mediated mRNA decay (NMD).18 However, it has
been shown that translation reinitiation abrogates NMD
in mammalian cells.19
About 60 larger deletions have been reported in patients
with MD.20–23 The majority have been identiﬁed in pa-
tients with classical symptoms. Here, we characterize the
effect of a deletion including exons 3 and 4, which was
identiﬁed in a patient with less-severe symptoms and long
survival. We characterize the effect on the resultingmRNA
transcript and protein product. Surprisingly, we found
that the transcript, though it contains a PTC, was not
recognized by the NMD machinery. Using a combination
of in vitro translation, immunocytochemical analysis, and
recombinant expression, we provide evidence that the
mutated transcript, designated “ATP7ADex3ex4 transcript,”
was protected from NMD because of reinitiation of protein
translation at two downstream internal AUG codons,
AUG461 and AUG475. The at-least-partial activity of the
resulting N-terminally truncated proteins containing only
CBS5 and CBS6 may contribute to the less-severe
phenotype.
Material and Methods
Patient
A.B. was born in England in 1973 with a birth weight of 2.92 kg.
At age 6 mo, he showed developmental delay, and, at age 2 years,
he started having seizures. At age 4 years, he developed head
control, and, at age 9 years, his motor and mental status was
assessed to be like that of a 3-mo-old child. At age 17 years, A.B.
had no speech, was hypotonic, and had brown, coarse hair. The
copper content and ceruloplasmin values in serum were slightly
reduced (7.3–8.9 mmol/liter copper, normal range 12.5–19 mmol/
liter; 0.5–1.0 mmol/liter ceruloplasmin, normal range 1.3–2.9
mmol/liter).24 In general, serum copper and ceruloplasmin levels
are ∼10% of normal in patients with MD.24 64Cu uptake and re-
tention studies performed on ﬁbroblasts from the patient showed
that 72.2% of 64Cu taken up over 20 h was retained in the cells
after an additional 24 h of efﬂux in normal medium (normal
range 9.0%–35.8%).25 Copper absorption from the gut was vir-
tually undetectable.24 A.B., who has never received any copper
treatment, is 35 years old but is severely mentally delayed. A
partial deletion of the ATP7A gene, including exons 3 and 4
(c.121-?_1338?del), is demonstrated in the patient (described as
“patient D11” elsewhere).21 A.B. has a maternal cousin with the
same mutation and essentially the same less-severe symptoms.24
Skin samples were collected from the patients for diagnostic in-
vestigations. Similar samples from healthy persons were used as
controls. The ﬁbroblasts were cultured as described elsewhere.26
Characterization of ATP7A mRNA
Total RNA was isolated from ∼ cells of cultured skin ﬁ-65# 10
broblasts, with the use of the RNeasy Mini Kit (Qiagen). Single-
stranded cDNA was synthesized by reverse transcription, with the
use of the High-Capacity cDNA Archive Kit, in accordance with
the manufacturer’s instructions (Applied Biosystems). cDNA was
used for PCR ampliﬁcation, with use of the primer pair
ATP7Aex1U/ATP7Aex6L (table 1) ﬂanking the genomic deletion
and Platinum Pfx DNA polymerase, in accordance with the man-
ufacturer’s instructions (Invitrogen). The obtained PCR product
was subsequently sequenced on an ABI PRISM 310 Genetic An-
alyzer, with use of the primers ATP7Aex1 and ATP7Aex6L (table
1) and Big Dye Terminator v.3.1 Cycle Sequencing Kit, in accor-
dance with the manufacturer’s instructions (Applied Biosystems).
Quantitative RT-PCR by Real-Time PCR
For relative quantiﬁcation of the mutated ATP7A transcript, real-
time PCR ampliﬁcation was performed on cDNA obtained from
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A.B. and from control mRNA samples. TaqMan FAM-probes and
primers annealing to the junction between exons 21 and 22 in
ATP7A (ATP7A 21/22 probe and primer pair ATP7Aex21/
ATP7Aex22 obtained using Assays-by-Design) (table 1) and to the
junction between exons 1 and 2 in ATP7A (TaqMan Gene Ex-
pression Assays [assay number Hs00921963_m1]) were purchased
from Applied Biosystems. As endogenous control, a VIC-probe
and primers to human GAPDH (Applied Biosystems [part number
4326317E]) were used. PCR ampliﬁcation and detection was per-
formed with an ABI7300 (Applied Biosystems), in accordance
with the manufacturer’s instructions. The threshold cycle (CT) is
deﬁned as the fractional cycle number at which the ﬂuorescence
passes a ﬁxed threshold. Standard curves of CT values compared
with log cDNA concentrations were prepared by assaying three-
fold serial dilutions of control cDNA, from 66.67 ng/well to 0.27
ng/well, with the GADPH and the ATP7A assays, respectively.
In Vitro Expression
For in vitro expression, fragments encoding N-terminal parts of
the mutated ATP7A protein were PCR ampliﬁed from cDNA with
ATP7A-speciﬁc primers in high-salt buffer, with the use of Taq
Plus Long, in accordance with the manufacturer’s instructions
(Stratagene). All the forward primers (T7-134-[-111], T7-M1, T7-
M461, T7-kozak-M461, and T7-kozak-M475) were designed to
carry a T7 promoter and were used in combination with the re-
verse primer, cATP7A642 (table 1). Transcription and translation
of the T7 promoter–containing PCR products were performed
using the TnT T7-coupled reticolocyte lysate system (Promega)
in the presence of 35S methionine (Amersham Pharmacia), in ac-
cordance with the manufacturer’s instructions. The synthesized
proteins were separated by SDS-PAGE (10% gels) under reducing
conditions, followed by ﬁxing (ﬁx-buffer: 10% v/v acetic acid and
50% v/v ethanol) and incubation for 30 min in Amplify Amer-
shamNAMP 100 (Amersham Pharmacia). The gel was driedbefore
exposure to Kodak X-Amat AR ﬁlm, XAR-5, at 80C for 24 h.
Western Blot Analysis of Endogenously and Recombinantly
Synthesized ATP7A Proteins
Fibroblasts were lysed in lysis buffer (50 mM Hepes [pH 7.6], 250
mM NaCl, 0.1% NP40, 5 mM EDTA, and 25 ml/ml Protease In-
hibitor Cocktail III [CalBioChem]) on ice for 30 min. Cell debris
was removed by centrifugation at 16,000 g for 5 min. Transiently
transfected CHO-1K cells were scraped into 1 ml PBS containing
25 ml/ml Protease Inhibitor Cocktail III, were pelleted, and were
resuspended in 50 ml PBS with protease inhibitors. Fibroblast and
CHO lysates were heated to 70C for 10 min and 95C for 5 min,
respectively, in the presence of LDS sample buffer (Pagegel Inc.)
and dithiothreitol. Proteins were separated on 8% SDS gels (Pa-
gegel Inc.) and were transferred to a precut nitrocellulose
membrane (Pagegel Inc.). The membranes were blocked by in-
cubation in blocking buffer (4% dry milk [Irma] in tris-buffered
saline [TBS] with 0.1% Tween-20) for 3 h. Incubation with pri-
mary and secondary antibodies was performed overnight at 4C
and for 1–2 h at room temperature, respectively, in blocking
buffer. The primary antibody, chicken anti-ATP7A (1:1,500)
(ab13995 from Abcam, recognizing amino acids 1407–1500), was
used for endogenous ATP7A proteins, whereas sc-789 rabbit anti-
Myc (1:200) (Santa Cruz Biotechnology) was used for recombi-
nant ATP7A proteins. The corresponding secondary horseradish
peroxide–conjugated antibodies were rabbit anti-chicken (1:
75,000) (Abcam ab6753) and swine anti-rabbit (1:1,000) (Dako).
Blots were developed for 5 min with the use of SuperSignal West
Pico Chemiluminescence kit (Pierce) and were exposed on Hy-
perﬁlm ECL (Amersham Biosciences) for 1–60 s.
ATP7A cDNA Constructs for Expression in Mammalian
Cells
In this study, we used the plasmid encoding the human wild-
type ATP7A cDNA sequence (GenBank accession number
L06133.1 [nucleotides 113-4645, except for the polymorphisms
1152TrA, 1535CrT, 2151CrT, and 3677CrT]), described else-
where.27 In this article, the construct is called “pCEP4ATP7Awt.”
The ATP7A protein encoded by this construct contains a Myc tag
fused inframe to the C-terminus. To generate an expression vec-
tor containing the ATP7ADex3ex4 cDNA sequence, we replaced a
NheI-BclI fragment of pCEP4ATP7Awt (NheI located in the poly-
linker of pCEP4 and BclI located in exon 9 at c.2220 in L06133.1)
with a corresponding fragment ampliﬁed from A.B. cDNA, with
the primers Nhe-ATP7AUTR (located upstream from the normal
AUG codon containing a NheI site) and ATP7Aex9L (table 1).
The resulting plasmid is called “pCEP4ATP7ADex3ex4.” Likewise,
the constructs pCEP4ATP7AD1460, pCEP4ATP7AD1474, and
pCEP4ATP7AD1460,M475L were prepared by PCR ampliﬁcation, with
the use of cDNA from A.B. and the forward primers Nhe-M461,
Nhe-M475, or Nhe-M461-M475L, respectively, in combination
with the antisense primer, ATP7Aex9L (table 1). All the cloned
PCR products were ampliﬁed with Platinum Pfx DNA polymerase
(Invitrogen), in accordance with the manufacturer’s instructions.
To digest the plasmidwith BclI, we propagated it in amethylation-
deﬁcient Escherichia coli strain, 2202 (araD139 D[ara-ABOIC-leu]
7679 gal E K D[lac] X74 relA rpsL spoT thi dam hsdR). After ligation,
transformation was performed using XL1-Blue cells (recA1 endA1
gyrA96 thi-1 hsdR17 supE44 relA1 lac [F′ proAB laclqZDM15 Tn10
(Tetr)]) (Stratagene). The cells were cultured at 30C for 3 d, to
obtain visible colonies. The entire ATP7A sequence was veriﬁed
by automatic sequencing.
Transient Transfections
CHO-1K cells (ATCC number CCL-61) were cultured at 37C with
5% CO2 in F12 growth medium (F12 medium [Gibco] supple-
mented with 10% v/v fetal calf serum [FCS], 100 U/ml penicillin,
and 100 mg/ml streptomycin). The day before transfection,
cells were seeded in 9.6 cm2 dishes and were incubated52.5# 10
for ∼24 h, to reach ∼60% conﬂuence. For each transfection, 1.5
mg of large-scale plasmid DNA, together with 7 ml of lipofectamin
(2 mg/ml) (Life Technologies), were used in accordance with the
manufacturer’s instructions. Cells were incubated for 6 h, fol-
lowed by the replacement of complexes with F12 growth me-
dium, in which cells subsequently were cultured for at least 24
h before further studies.
Indirect Immunoﬂuorescence Detection of ATP7A Proteins
Transiently transfected CHO-1K cells grown on glass coverslips
were treated after 48 h, with either 50 mM bathocuproine disul-
fonic acid (BCS [Sigma]) or 200 mM CuCl2 in F12 medium for 2
h. Cells were ﬁxed with20C cold methanol for 5 min at20C
and were incubated in F12 with 10% v/v FCS for 30 min, to block
unspeciﬁc signals. Doubled labeling was performed by incubation
with antibodies for 1 h in blocking media. Primary antibodies
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used were rabbit anti-Myc ( ) (Santa Cruz Biotechnologies)1:50
and mouse anti-GS28 ( ) (BD Biosciences). Secondary an-1:1,000
tibodies were goat anti-rabbit, Alexa 488 ( ), and donkey1:1,500
anti-mouse, Alexa 548 ( ) (Molecular Probes). Coverslips1:1,500
were mounted with Dapi Antifade ES (Cytocell).
Fibroblasts obtained from A.B. and control persons were treated
as described elsewhere,28 with a minor modiﬁcation. Instead of
50 mM BCS, a concentration of 150 mM BCS was used. As positive
controls, ﬁbroblasts from unaffected persons were used, and, as
negative controls, ﬁbroblasts from a patient with MD with de-
letion of exons 3–23 (c.121-?-8333?del) were used.
ATP7A cDNA Constructs for Expression in Yeast Cells
For expression of ATP7A constructs in yeast, the ATP7A sequences
were cloned in the low-copy, URA3-encoding expression vector,
pRS316GPD, under the control of the constitutively active glyc-
eraldehydes-3-phosphate dehydrogenase (GPD) promoter. This
vector was derived from pRS316,29 by insertion of the GDP pro-
moter isolated from the multicopy expression vector, pG-1,30 with
the use of BamHI and HindIII. The entire wild-type ATP7A cDNA
sequence was isolated from pCEP4ATP7Awt and was inserted into
pRS316GPD with the use of NotI. The resultant plasmid served
as starting material for cloning of the different ATP7A cDNA var-
iants modiﬁed to the yeast system. The fragment from SpeI (re-
striction site in the polylinker of pRS316) to BclI (restriction site
in exon 9 in the ATP7A sequence) was swapped with different
NheI- and BclI-digested PCR products. All forward primers (see
below) containing a NheI restriction site and a poly A sequence
(the translation-initiation consensus sequence in yeast is, pre-
sumably, 10 As31) were combined with the reverse primer,
ATP7Aex9L (table 1). For preparation of pRS316GPDATP7Awt
and pRS316GPDATP7ADex3ex4, control and A.B. cDNAs, respec-
tively, were used as template with the forward primer yeast-
M1 (table 1). For preparation of pRS316GPDATP7AD1460,
pRS316GPDATP7AD1474, and pRS316GPDATP7AD1460,M475L, the
forward primers yeast-M461, yeast-M475, and yeast-M461-
M475L, respectively, were used with control cDNA as template
(table 1).
Yeast Transformation
We used the wild-type Saccharomyces cerevisiae strain 7 (MATa
his3-200 leu2 trp1-101 ura3-52 ade5) and the ccc2 mutant strain
8 (MATa his3-200 leu2 trp1-101 ura3-52 ade5 Dccc2::LEU2) de-
scribed elsewhere.32,33 Yeast transformations were performed us-
ing the Yeastmaker Yeast transformation system 2 kit (Clontech):
strains 7 and 8 were cultured overnight at 30C at 200 rpm in
YPD-A medium (10 g/liter Bacto Yeast Extract [Difco], 20 g/liter
Bacto peptone [Difco], 0.1 g/liter adenine [Sigma], and 2%glucose
monohydrate [Merck]). Cells from 0.5 ml culture in log phase
were pelleted, and 100 mg freshly denaturated (5 min at 100C)
Herring Testes Carrier DNA, with 1 mg transforming DNA
(pRS316GPD-derived, with URA3 marker), was added. Half a mil-
liliter of a solution containing 40% PEG 4000, 0.1 M LiAc, 10
mM Tris-HCl (pH 7.5) and 1 mM EDTA. In addition, 57 ml di-
methyl sulfoxide was added, followed by incubation at room tem-
perature for 15 min and heat shock at 42C for an additional 15
min. The transformed cells were pelleted by centrifugation, were
resuspended in 200 ml TE (10 mM Tris-HCl [pH 7.5] and 1 mM
EDTA), were spread on synthetic-deﬁned (SD) plates without ura-
cil (27.4 g/liter, SD-ura-leu [Bio-101], 40 g/liter bacto agar [Difco],
and 300 mg/liter l-leucin [Merck]), and were cultured at 30C for
3 d.
Complementation Test
Uracil prototrophic colonies were tested for ATP7A protein func-
tion in iron-limited medium, with the use of a method modiﬁed
from Forbes and Cox.34 Cells were cultured overnight at 30C in
liquid SD medium without uracil, reaching a late log phase. Cells
were pelleted, were washed in sterile water, and were cultured
overnight after a 1:10 dilution in liquid iron-limited medium (as
described by Forbes and Cox,34 with the exception that trypto-
phan was included and uracil was excluded from the medium).
Growth curves and complementation test on plateswere prepared
as described elsewhere.34 The plates were photographed after 3–
4 d at 30C and 37C.
Results
Predicted Consequence of the Mutation in the Patient with
Less-Severe MD
The patient, A.B., investigated in this study showed re-
markably long survival and less-severe symptoms, in spite
of what we would expect to be a severe mutation in the
ATP7A gene. A.B. (patient D1121) has a partial deletion of
the ATP7A gene, including exons 3 and 4 (c.121-
?_1338?del). This allele is designated in this article as
“ATP7ADex3ex4.” To test the effect of the mutation on the
resulting ATP7A mRNA transcript, we analyzed mRNA
isolated from A.B. ﬁbroblasts. RT-PCR ampliﬁcation of
the mRNA fragment, from exon 1 to exon 6, led to a 440-
bp product (ﬁg. 1, lane P), whereas the expected 1,650-
bp product was obtained from control ﬁbroblasts (ﬁg. 1,
lane C). Sequence analysis of the 440-bp PCR product
revealed that exon 2 was followed directly by exon 5
(r.12_1338del). The deletion changes the reading frame
and introduces a PTC in exon 5 (p.V41fsTX7) (ﬁg. 2).
Quantiﬁcation of ATP7ADex3ex4 Transcript in Patient Cells
Transcripts with PTCs will normally be degraded by
NMD.18 To investigate the stability of the ATP7ADex3ex4
transcript, the relative amount of this transcript was mea-
sured using real-time PCR. Two different ATP7A TaqMan
assays were used—one detecting the junction between ex-
ons 21 and 22, located downstream from the deletion,
and one detecting the junction between exons 1 and 2,
upstream from the deletion. An assay detecting GAPDH
was used as endogenous control, to normalize for differ-
ences in cDNA input in the samples. Patient and control
cDNA samples (fourfold serial dilutions from 37.5 ng to
2.3 ng) were assayed with the GAPDH and the ATP7A as-
says. The results obtained from samples estimated to con-
tain 9.4 ng of cDNA are given in table 2. For both ATP7A
assays, we did not ﬁnd any signiﬁcant difference in the
amount of ATP7A transcript in patient cells compared
with that in control cells, when normalized to GAPDH.
Results obtained using other cDNA concentrations did not
differ from those reported in table 2 (data not shown).
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Figure 1. Characterization of patient ATP7A mRNA. PCR ampli-
ﬁcation of exons 1–6 was performed on cDNA obtained from RNA
isolated from ﬁbroblasts from patient A.B. (P) and from an un-
affected control person (C). The PCR products were separated on
a 1% agarose gel and were visualized by ethidium bromide staining.
M, Sizes (in bp) of the marker DNA fragments.
This result suggested that the mutation did not affect the
stability of the transcript. One reason could be reinitation
of protein translation, which has been found to abrogate
NMD.19
In Vitro Translation Indicates Initiation at Downstream
AUG Codons
The ATP7ADex3ex4 protein is predicted to consist of only
46 amino acids (ﬁg. 2) and is unlikely to have any copper-
transporting function. To test whether the ATP7ADex3ex4
transcript encodes alternative protein products, we ana-
lyzed the part of the transcript encoding the N-terminal
part of the protein, using RT-PCR combined with a cou-
pled in vitro transcription/translation. The primer pair T7-
M1/cATP7A642 (table 1) was used to amplify the coding
sequence of cDNA from the ATG start codon 1, located in
exon 2, to codon 642, located in exon 8. In vitro tran-
scription/translation of the resulting PCR product, ob-
tained from a control person, results in the formation of
a 70-kDa protein product (ﬁg. 3, lane 2), in concordance
with the synthesis of 642 aa of the wild-type protein. The
same test performed on A.B. cDNA leads to the formation
of two protein products of ∼20.5 kDa and ∼23 kDa (ﬁg.
3, lane 3), both of which are substantially larger than the
expected 5-kDa product encoded by the 46 codons from
the start codon to the PTC. This result indicates in vitro
reinitiation of translation.
To identify possible translation-reinitiation sites, we
screened the mRNA sequence for AUG codons down-
stream from the PTC in the normal reading frame, at
which translation-initiation would give rise to protein
products of the observed sizes. Two codons, AUG461 and
AUG475, corresponding to p.M461 and p.M475, respec-
tively, were found in exon 5 (ﬁg. 2). When a forward
primer annealing to the sequence starting at the AUG461
codon was used, the ampliﬁed PCR product was devoid
of exon 1, exon 2, and the part of exon 5 upstream from
AUG461. In vitro transcription/translation of the resulting
PCR product (T7-M461/cATP7A642) also leads to the for-
mation of two protein products of ∼20.5 kDa and ∼23 kDa
(ﬁg. 3, lanes 4 and 5). Apparently identical products were
obtained from both control and A.B. cDNA. The ∼20.5-
kDa protein was the most abundant.When the translation
start at the AUG461 codon was favored, with use of a
forward primer containing a consensus eukaryotic trans-
lation-initiation signal (Kozak, ACCACC) upstream from
the codon (T7-kozak-M461), the larger ∼23-kDa product
became the most abundant (ﬁg. 3, lanes 6 and 7). With
use of a forward primer annealing to the sequence starting
at the AUG475 codon (T7-kozak-M475), the possibility of
translation start at AUG461 was abolished, and only the
∼20.5-kDa product was produced (ﬁg. 3, lanes 8 and 9).
The 20.5-kDa and 23-kDa products are in accordance with
the expected size of proteins containing 168-aa residues
(amino acids 475–642) and 189-aa residues (amino acids
461–642), respectively. These results suggest that protein
translation in vitro is reinitiated at the two codons
AUG461 and AUG475.
Two alternative AUG start codons in different reading
frames are located in exon 2, upstream from the normal
AUG start codon 1 (ﬁg. 2). To test if the 5′ UTR region also
including these alternative AUG codons had any effect on
the results obtained by in vitro translation, we designed
a T7-containing forward primer that anneals to the more-
upstream–located sequence c.-134-(-111) in exon 1 (ﬁg.
2). In vitro translation of the resulting PCR product leads
again to the synthesis of the 20.5-kDa and 23-kDa prod-
ucts, with apparently the same efﬁciency (data not shown).
Thus, the synthesis of these proteins was still possible in
the presence of a part of the 5′ UTR region, mimicking to
a higher degree the composition of the ATP7ADex3ex4 tran-
script present in A.B. On the other hand, the presence of
the 5′ UTR region seems to not enhance the efﬁciency of
the synthesis of the 20.5-kDa and 23-kDa products.
Analysis of ATP7A Protein in Cell Lysate Obtained from
Cultured Patient Fibroblasts
To test for the presence of alternative ATP7ADex3ex4-en-
coded proteins in A.B. cells, we performed western blot-
ting with total cell lysate obtained from cultured ﬁbro-
blasts. We used an anti-ATP7A antibody raised against the
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Figure 2. Expected cDNA sequence of ATP7ADex3ex4. Lowercase letters indicate part of the 5′ UTR, and uppercase letters indicate exons
1, 2, and 5. The predicted normal amino acid sequence (one letter) is indicated below the DNA sequence. Italic letters above the DNA
sequence indicate predicted amino acids as a consequence of frameshifting. The vertical lines indicate the exon 1/2 and exon 3/5
junctions. The normal translation-initiation ATG codon in exon 2 is underlined and highlighted. Alternative ATG codons in exon 2 are
underlined, and the ATG461 and ATG475 codons in exon 5 are underlined and indicated by number. The position of the T7-containing
forward primer T7c.-134-(-111) is indicated. The numbering is in accordance with the normal ATG1 start codon in exon 2.
15 most C-terminal amino acids. An ATP7Awt protein of
∼170 kDa was detected in unaffected control ﬁbroblasts
but not in the negative control ﬁbroblasts (ﬁg. 4, lanes C
and N, respectively). No ATP7A signal was obtained in
ﬁbroblasts from A.B. (ﬁg. 4, lane P).
Cellular Localization of the Protein Variants in Cultured
Patient Fibroblasts
Although it was not possible to identify any ATP7A pro-
teins in cell extract obtained from the patient by western
blotting, we wanted to test if ATP7A proteins could be
identiﬁed by immunoﬂuorescence (IF). We used the same
primary anti-ATP7A antibody, combined with not only a
secondary but also a tertiary Alexa 488–conjugated anti-
body, to enhance the signal. With the use of this system,
it was possible to identify the ATP7ADex3ex4 protein in A.B.
ﬁbroblasts (ﬁgs. 5 and 6). At physiological conditions, the
copper content in cells is very low, and, to reﬂect this
condition, cells were treated with BCS, which speciﬁcally
complexes Cu(I) ions. A closely to completely overlapping
signal from the ATP7Awt protein and the TGN-localized
GS28 SNARE protein35 was observed in almost all the pos-
itive control cells after treatment with 150 mM BCS (ﬁgs.
5 and 6A). In the A.B. cells, the ATP7A signal was faint
and slightly more diffused. However, the ATP7ADex3ex4
protein was visible in about half of the cells, and, in the
major part of these, the signal was located in TGN, in
similarity with the signal present in positive control ﬁ-
broblasts (ﬁgs. 5, 6A, and 6B). However, in contrast towhat
we observed for the positive control cells, a reduced con-
centration of BCS (50 mM) was not sufﬁcient to obtain
concentrated Golgi localization of the ATP7A signal in the
A.B. cells (data not shown). No speciﬁc ATP7A signal could
be detected in the negative control cells (ﬁg. 5). A non-
speciﬁc signal was observed as spheres in the nucleus and
as spots in the cytoplasm, but the nonspeciﬁc signal was
easily distinguishable from the much stronger signal ob-
served in the control and A.B. cells.
Furthermore, we analyzed whether the mutation affects
the copper-dependent trafﬁcking normally observed for
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Table 2. Expression of ATP7A Transcript in Patient Fibroblasts
Sample
ATP7AN
Valuea
ATP7AN Value
Relative to
Unaffected
Controlsb
Probe against the exon 20/21 junction:
Control:
1c .91 …
2d .83 …
3d .89 …
4d 1.20 …
Average .96  .16 1.00  .17
Patient:
Experiment Ac .99 1.03
Experiment Bd 1.39 1.46
Experiment Ce 1.00 1.04
Average 1.13  .23 1.18  .21
Probe against the exon 1/2 junctionf:
Control:
1 1.10 …
2 1.02 …
3 1.71 …
Average 1.28  .38 1.00  .29
Patient (experiment D) 1.31 1.03
NOTE.—Quantiﬁcations of transcripts in the patient cells were performed three
independent times with the probe against the exon 21/22 junction (experiments
A, B, and C) and one time with the probe against the exon 1/2 junction (experiment
D), with essentially the same result. In experiment A, one unaffected control was
included, and, in experiments B and D, three unaffected controls were included.
In all experiments, the amounts of ATP7A and GAPDH RNA were calculated by
linear regression of the lines generated by the standard curves, log cDNA con-
centration against CT. Averages of several experiments appear in bold type.
a Normalized ATP7AN value is calculated by dividing the ATP7A RNA value by
the GAPDH RNA value (SDs are shown).
b ATP7AN value relative to unaffected control ﬁbroblasts is calculated by dividing
the normalized ATP7A value by the average ATP7AN value obtained from control
ﬁbroblasts (SDs are shown).
c Experiment A: for GAPDH; forYp 3.57X 24.41 Yp 3.49X 32.96
ATP7A.
d Experiment B: for GAPDH; forYp 3.49X 24.34 Yp 3.10X 31.99
ATP7A.
e Experiment C: for GAPDH; forYp 3.60X 25.87 Yp 3.41X 31.29
ATP7A.
f Experiment D: for GAPDH; forYp 3.49X 24.34 Yp 3.10X 31.99
ATP7A.
ATP7Awt.13,14 In cells cultured in media supplementedwith
200 mM CuCl2, a diffuse ATP7A staining was found in both
the positive control cells and the A.B. cells. A part of the
ATP7A staining was still overlapping with the Golgi-lo-
cated GS28, but a fraction was also scattered in the cy-
toplasma or was located perinuclear (ﬁg. 5). No cells with
persistent, concentrated, TGN-located ATP7A signal were
observed (ﬁg. 6A).
These results suggest thatmutatedATP7ADex3ex4proteins
are synthesized in A.B. ﬁbroblasts and that the C-terminal
part of the proteins is identical to the ATP7Awt protein,
since an antibody against the 15 most C-terminal amino
acids recognized it. In accordance with the intensity of
the signal (ﬁg. 6B), the amount of ATP7ADex3ex4 was re-
duced in comparison to the amount of ATP7Awt synthe-
sized in the positive control cells, which might explain
the lack of signal with the use of western blotting. In ad-
dition, the ATP7ADex3ex4 proteins might be sensitive to the
lysis treatment performed during western blotting. The
mutation probably affects the cellular copper concen-
tration but not, or only slightly, the copper-dependent
trafﬁcking of the ATP7ADex3ex4 proteins. An increase in
intracellular copper concentration is expected, secondary
to the impaired copper efﬂux measured in the A.B.
ﬁbroblasts.
Expression of ATP7A Variants in Cultured CHO Cells
To test whether it was possible to synthesize in vivo the
protein products predicted by the in vitro study, we gen-
erated a recombinant construct encoding theATP7ADex3ex4
cDNA sequence (ﬁg. 7) and introduced it into the plasmid
pCEP4ATP7Awt, in place of the ATP7Awt sequence. Plas-
mids expressing the wild-type and mutant alleles were
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Figure 3. A coupled in vitro transcription/translation of the
ATP7ADex3ex4 transcript indicates reinitiation of translation at the
two internal codons AUG461 and AUG475. On A.B. (P) and control
(C) cDNA, different primer pairs were used to PCR-amplify se-
quences encoding N-terminal fragments. The T7-containing PCR
products were transcribed and translated in vitro, in the presence
of 35S methionine, and were analyzed by SDS-PAGE. The used primer
pairs were T7-M1/cATP7A642 (lanes 2 and 3), T7-M461/cATP7A642
(lanes 4 and 5), T7-kozak-M461/cATP7A642 (lanes 6 and 7), and
T7-kozak-M475/cATP7A642 (lanes 8 and 9). Rainbow 14C-methyl-
ated proteins (Amersham) were used as molecular-weight markers
(M).
Figure 4. No ATP7ADex3ex4 protein could be identiﬁed by western
blotting analysis in cell extract from A.B. ﬁbroblasts. Proteins in
total cell lysates from ﬁbroblasts were separated by SDS-PAGE,
followed by immunoblotting with antibody to the ATP7A protein.
The results of lysates obtained from positive control cells (C),
negative control cells (c.121-?-8333?del) (N), and A.B. cells (P)
are shown. Kaleidoscope Prestained standard was used as a mo-
lecular marker (Biorad).
transiently transfected into CHO cells. Proteins encoded
by these constructs contain an inframe, C-terminal Myc
tag and are recognized by an antibody against this epitope.
The proteins synthesized were examined by western
blotting (ﬁg. 8). From the pCEP4ATP7Awt plasmid, a 170-
kDa protein is synthesized, and a protein of 120 kDa is
synthesized from pCEP4ATP7ADex3ex4. The 170-kDa pro-
tein correlates with the expected size of the 1,500-aa-
long wild-type protein. The 120-kDa protein correlates
with a truncated protein containing only two CBSs. This
indicates that protein translation not only in vitro but also
in vivo is reinitiated at an internal AUG codon. Since
proteins encoded by pCEP4ATP7Awt as well as by
pCEP4ATP7ADex3ex4 were recognized by the antibody
against Myc, this result also suggests that the internal re-
initiation AUG codon is in the same reading frame as
the normal AUG codon. This result suggests that the
ATP7ADex3ex4 proteins lack the ﬁrst four CBSs, whereas the
remaining C-terminal fragment of the proteins is identical
to the ATP7Awt protein. It is, however, not possible to de-
cide whether one or two protein products are synthesized
from pCEP4ATP7ADex3ex4.
The molecular weight of the pCEP4ATP7ADex3ex4-en-
coded proteins suggests that in vivo reinitiation also takes
place at the internal codons AUG461 and AUG475. To test
this hypothesis further, we generated two constructs
optimized to express the truncated ATP7A proteins initi-
ated at p.M461 (r.1_1380del) and p.M475 (r.1_1422del).
These constructs, designated “pCEP4ATP7AD1460” and
“pCEP4ATP7AD1474” were devoid of exon 1, exon 2, and
the part of exon 5 upstream from the expected restart AUG
codons; furthermore, they were cloned with a Kozak con-
sensus sequence upstream from the selected AUG codon
(ﬁg. 7). To be able to examine a protein product initiated
at p.M461 alone, without the presence of a product ini-
tiated at p.M475, we generated a third construct,
pCEP4ATP7AD1460,M475L, that encodes a protein initiated
at p.M461 combined with the mutation p.M475L
(r1_1422del1423ArC). The proteins synthesized from
these three constructs migrate in the same way as the
protein synthesized from pCEP4ATP7ADex3ex4 (ﬁg. 8),
which supports the hypothesis that reinitiation also takes
place at the AUG461 and AUG475 codons in vivo.
To investigate the cellular localization of the recombi-
nant, truncated ATP7A proteins, we analyzed CHO cells
transiently transfected with the different plasmids. By
double IF studies, we found that the major part of the
ATP7Awt protein encoded by pCEP4ATP7Awt colocalizes
with GS28 in the presence of 50 mM BCS (ﬁgs. 5 and 6A).
The localization of the protein variants encoded by
pCEP4ATP7ADex3ex4 was slightly more diffused, in agree-
ment with what we observed for the endogenous
ATP7ADex3ex4 protein synthesized in A.B. ﬁbroblasts (ﬁg.
6A). However, a large fraction of the recombinantly
synthesized ATP7ADex3ex4 protein also seems to be cor-
rectly located in the TGN (ﬁg. 6A). Similarly, a large frac-
tion of pCEP4ATP7AD1460-, pCEP4ATP7AD1474-, and
pCEP4ATP7AD1460,M475L-encoded protein products colocal-
ized with GS28 (ﬁg. 6A). To investigate if the protein var-
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Figure 5. The endogenously and recombinantly synthesized ATP7ADex3ex4 protein shows a copper-dependent trafﬁcking. Fibroblasts
and transiently transfected CHO cells were cultured in the presence of CuCl2 or BCS, as indicated, to test the effect of the deletion of
exons 3 and 4 on the copper-dependent trafﬁcking. Fibroblasts from A.B. (P), positive control ﬁbroblasts from unaffected persons (C),
and negative control ﬁbroblasts from a patient with MD with deletion of exons 3–23 (c.121-?-8333?del) (N) were analyzed. The
analyzed CHO cells were transfected with pCEP4ATP7ADex3ex4 and with different constructs optimized to express the truncated ATP7A
proteins initiated at p.M461 (pCEP4ATP7AD1460 and pCEP4ATP7AD1460,M475L) and at p.M475 (pCEP4ATP7AD1474). CHO cells transfected
with pCEP4ATP7Awt and empty vector (EV) pCEP4 were used as positive and negative controls, respectively. Fixed cells were subjected
to double-IF staining for the ATP7A protein (green) and the TGN marker GS28 (red). The combined images are shown (yellow). Images
were viewed using a 100# oil objective.
iants were able to trafﬁc in response to copper, we incu-
bated transfected CHO cells with 200 mMCuCl2. As a result
of copper treatment, the intensities of ATP7Awt and of the
different ATP7A variants in TGN decreased, and a staining
throughout the cytoplasma appeared in the major part of
the cells (ﬁgs. 5 and 6A). Indistinguishable staining pat-
terns were seen for all tested protein variants.
Since the cellular localization and copper-dependent
trafﬁcking of the recombinantly and the endogenously
synthesized ATP7ADex3ex4 proteins are similar, these results
support the hypothesis that the endogenously synthesized
ATP7ADex3ex4 variants are identical to proteins encoded by
pCEP4ATP7ADex3ex4, which might be identical to the pro-
teins encoded by pCEP4ATP7AD1460 andpCEP4ATP7AD1474.
Furthermore, lack of the four N-terminal CBS1–CBS4 did
not appear to substantially affect the localization or traf-
ﬁcking of the ATP7A protein, in agreement with results
published elsewhere.36
Complementation of a Dccc2 Yeast Strain by Expression of
Constructs Encoding ATP7A Variants
To investigate the biological function of the mutated
ATP7A proteins, we cloned the wild-type and different
mutated cDNA forms into the low-copy yeast expression
vector, pRS316GPD, for introduction into the yeast strain
Dccc2 lacking the CCC2 gene, the yeast homologue to
ATP7A. In S. cerevisiae, Ccc2p is responsible for the incor-
poration of copper into the copper-requiring ferroxidase
Fet3p, a ceruloplasmin homologue necessary for high-
afﬁnity iron uptake.32 As a consequence, a Dccc2 yeast
strain is deﬁcient in high-afﬁnity iron uptake, a pheno-
type that is detected by reduced growth under iron-
limited conditions (ﬁg. 9A). The wild-type yeast strain
showed no growth phenotype on iron-limited medium
(ﬁg. 9A). All the constructs—pRS316GPDATP7Awt,
pRS316GPDATP7ADex3ex4, pRS316GPDATP7AD1460,
pRS316GPDATP7AD1474, and pRS316GPDATP7AD1460,
M475L—encoding recombinant ATP7A proteins were able to
complement the Dccc2 iron-deﬁcient phenotype at 30C;
thus, they allowed cells to grow under iron-limited con-
ditions (ﬁg. 9A), indicating that they were at least partially
functional. These data suggest that reinitiation of the
ATP7ADex3ex4 cDNA sequence containing the 46-codon
ORF upstream from the expected restart AUG codons is
possible not only in mammals but also in yeast. Interest-
ingly, at 37C, the construct pRS316GPDATP7ADex3ex4 was
no longer able to complement, whereas complementation
was still observed with the remaining constructs (ﬁg. 9D).
At 37C, the truncated protein is likely less stable, and the
reinitiation efﬁciency might be too low to produce a suf-
ﬁcient amount for complementation. Addition of copper
(ﬁg. 9B and 9E) or iron (ﬁg. 9C and 9F) rescued all trans-
formed cells at both 30C and 37C. To more closely deﬁne
the complementation efﬁciency of the mutant constructs,
we analyzed the doubling time at 30C in liquid iron-
limited medium. The doubling time was calculated on the
basis of OD600 measurements of exponentially growing
cultures. The growth rate of the Dccc2 yeast cells trans-
formed with the different mutants was not signiﬁcantly
different from the pRS316GPDATP7Awt-transformed cells
(Student t test ) (ﬁg. 10). The almost normal growthP ! .05
rate at 30C supports the notion that the ATP7ADex3ex4 pro-
tein is at least partially functional, consistent with the less-
severe phenotype of A.B.
Discussion
Here, we report, for the ﬁrst time, moderation of the clin-
ical phenotype in a patient with MD by partially func-
tional truncated proteins synthesized as a result of trans-
lation reinitiation. The patient had a less-severe pheno-
type, despite a large frameshift gene deletion. Surprisingly,
we found that, although it contains a PTC, the transcript
was protected from NMD. The predicted product of the
ATP7ADex3ex4 transcript consists of only 46 aa, which is
extremely unlikely to mediate any copper translocation.
Therefore, we used an in vitro translation system to test
the hypothesis that the ATP7ADex3ex4 transcript encodes
alternative proteins. We found that the transcript directed
the synthesis of N-terminally truncated proteins by rein-
itiation at the downstream codons AUG461 and AUG475.
Transfection studies conﬁrmed the synthesis of proteins
of a size consistent with the predicted reinitiation codons.
Using an antibody against the C-terminus, we detected
endogenously synthesized ATP7A in patient ﬁbroblasts,
which supports the formation of an N-terminally trun-
cated protein.
Translation Initiation from Internal AUG Codons
Translation in eukaryotes is normally initiated at the ﬁrst
AUG codon closest to the 5′ end, as long as it resides in
the optimal context: GCCRCCAUGG. The purine R in po-
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Figure 6. Quantiﬁcation of the effect of CBS1–CBS4 on cellular
localization by IF microscopy. A, Percentage of positive cells with
ATP7A signal concentrated in TGN, compared with positive cells
with more diffuse staining. The cells were treated with CuCl2 or
BCS, as indicated. The total number of positive cells is deﬁned as
100%. A.B. ﬁbroblasts (P), positive control ﬁbroblasts (C), and
negative control ﬁbroblasts (N), in addition to CHO cells trans-
fected with pCEP4ATP7Awt, pCEP4ATP7ADex3ex4, pCEP4ATP7AD1460,
pCEP4ATP7AD1474, pCEP4ATP7AD1460,M475L, and EV pCEP4 were in-
vestigated. More than 100 cells of each type were analyzed. B,
Percentages of cells with a positive ATP7A signal, a less-positive
signal, and no signal were determined. A.B. ﬁbroblasts (P) and
positive control ﬁbroblasts (C) treated with BCS were investigated.
More than 100 cells of each type were analyzed.
Figure 7. Schematic diagram of the ATP7A constructs. Exons 1–
6 of ATP7A are depicted as separate small boxes. Exons 7–23 are
depicted as a big black box. The predicted N-terminal amino acids
are indicated. All the constructs encode an inframe C-terminal Myc
tag.
sition 3 (G or A, where A is preferred) and the G in
position4 are the most important (reviewed in Kozak37).
However, studies have shown that, when a PTC shortly
follows the ﬁrst AUG codon, the ribosomes move forward
to reinitiate at downstream internal AUG codons.38 By in-
vestigating plasmid constructs, reinitiation was found to
be optimal after translation of an ORF between 13 and 55
codons.38,39 Since the ﬁrst ORF inATP7ADex3ex4 is 46 codons
in length, the conditions for reinitiation are met in this
study, and we propose that translation initiates at the nor-
mal AUG1 codon, producing a 46-aa-long peptide, fol-
lowed by reinitiation at AUG461 and AUG475.
It has been demonstrated elsewhere40 that reinitiation
is not limited to the closest AUG beyond the 5′-proximal
ORF. If the ribosomal subunits, which only gradually be-
come competent, are not yet ready when they reach the
ﬁrst AUG codon downstream from the PTC, they continue
scanning, initiating at an AUG codon(s) further down-
stream.40 This phenomenon might explain why we found
reinitiation at both the AUG461 codon and the AUG475
codon. Alternatively, it might be the result of leaky scan-
ning, since the AUG461 resides in the weak context UCA-
UCGGAAAUGC (ﬁg. 2).
Very few studies have previously demonstrated reinitia-
tion of translation in patients suffering from inherited dis-
orders. Thus, in patients suffering from peroxisome-bio-
genesis disorder, methylmalonic acidemia, or androgen
resistance, reinitiation has been demonstrated after trans-
lation of ORFs of 8, 17, or 59 codons, respectively.41–43
Interestingly, in a patient suffering from peroxisome-bi-
ogenesis disorder, because of two different mutations in
the PEX12 alleles, reinitiation of one of two mutated tran-
scripts was proposed to modulate the phenotype.41 To our
knowledge, this is the only previous demonstration of
translation reinitiation proposed to modulate the disease
phenotype of a patient. Since peroxisome-biogenesis dis-
order due to PEX12 mutations is autosomally inherited,
interpretation is more complicated than for the present
X-linked MD.
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Figure 8. Western blotting shows that a protein of ∼120 kDa is
synthesized from pCEP4ATP7ADex3ex4, which is consistent with rein-
itation at ATG461 and ATG475. Cell lysates from CHO cells tran-
siently transfected with pCEP4ATP7ADex3ex4, pCEP4ATP7AD1460,
pCEP4ATP7AD1474, and pCEP4ATP7AD1460,M475L were subjected to
SDS-PAGE and immunoblotting, with the use of antibody to the
Myc epitope tag. CHO cells transfected with pCEP4ATP7Awt and EV
pCEP4 were used as positive and negative controls, respectively.
Aliquots of 3–15 ml total cell lysate (∼6–30 mg total protein) were
loaded to obtain approximately equal signal intensity in all lanes.
Abrogation of NMD
Transcripts with PTC are generally low in abundance, be-
cause of decay.18,44 However, some exceptions from this
rule have been described. Transcripts containing PTC po-
sitioned in close proximity to the initial codon in triose-
phosphate isomerase constructs and in b-globin and
BRCA1 mRNA have been found to be, at least partially,
NMD resistant.19,45,46 For triosephosphate isomerase con-
structs, this resistance was caused by reinitation of trans-
lation,19 whereas it does not seem to be the case for b-
globin mRNA.46
The normal amount ofATP7A transcript in cultured skin
ﬁbroblasts from the patient indicates that theATP7ADex3ex4
transcript containing a PTC at codon 47 is not recognized
by the NMD machinery. We found that the level of ATP7A
transcripts containing a PTC after ORFs of 305 and 425
codons was !15% of the level found in controls (data not
shown [L. B. Møller, unpublished results]). Testing the 5′
ends of these mutated cDNAs by the in vitro transcription/
translation system did not reveal any reinitiation (datanot
shown). Thus, PTC-containing ATP7A transcripts seem to
behave as predicted from the literature18,19,44 and are not
always protected against NMD. In conclusion, our results
suggest that the ATP7ADex3ex4 transcript containing an
early PTC is protected from degradation as a consequence
of reinitiation.
Partially Functional Activity of the N-Terminally Truncated
Proteins Containing CBS5 and CBS6
We observed cellular localization and copper-dependent
trafﬁcking of endogenous and recombinant ATP7ADex3ex4
proteins similar to that of the ATP7Awt protein, with one
major exception. A higher concentration of BCS was nec-
essary to obtain Golgi localization of the endogenous
ATP7ADex3ex4 proteins, compared with ATP7Awt. The
higher cellular copper content observed in the A.B. ﬁbro-
blasts might explain this difference in sensitivity to the
copper chelator BCS.
This observation is consistent with previously published
results, showing that CBS1–CBS4 in neither ATP7A nor
ATP7B is necessary for copper-dependent trafﬁcking.36,47
However, since CHO cells expressing theATP7ADex3ex4 con-
struct also had a lower percentage of TGN-concentrated
ATP7A signal compared with the ATP7Awt-expressing cells,
we cannot exclude the possibility that the deletion of the
four CBSs makes the ATP7A protein more sensitive to
copper.
The Dccc2 strain was complemented by constructs ex-
pressing the ATP7ADex3ex4 proteins, indicating that the
proteins are able to load Fet3p with copper to regain high-
afﬁnity iron uptake. In a previous study, a similar con-
struct encoding a Menkes protein without the ﬁrst four
CBSs was found to complement almost as well.17 The mi-
nor difference in complementation efﬁciency can be ex-
plained by the difference in the constructs; the construct
of Mercer’s group encodes a protein lacking amino acids
8–485, whereas the proteins tested in this study lack the
amino acids 1–460 or 1–474. For the Wilson protein, it
has been demonstrated that the sixth CBS alone is sufﬁ-
cient for complementation.48 It was found that a Wilson
cDNA construct with all the cysteines in CBS1–CBS5 mu-
tated, as well as a construct where CBS1–CBS5 were de-
leted, were able to complement the Dccc2 strain.48
Consistent with the functional properties of the
ATP7ADex3ex4 proteins, serum levels of copper and ceru-
loplasmin in A.B. were reduced to only ∼50% of normal.
In patients with typical MD, levels are reduced to ∼10%.24
The hair had no pili torti, as is normally seen in MD pa-
tients. A.B. has had a long survival, similar to patientswith
OHS, whereas patients with classical MD typically die be-
fore they are 3 years old. That the overall activity of the
ATP7ADex3ex4 proteins was not sufﬁcient to obtain ho-
meostatic copper balance was, however, clear. Although
A.B., in contrast to patients with typical MD, was able to
achieve minor improvements, he has severe neurological
symptoms: mental delay, epileptic seizures, and no
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Figure 9. N-terminally truncated Menkes proteins complement a ccc2 yeast strain by restoring high-afﬁnity iron uptake. The Dccc2
strain 8 was transformed with EV (pRS316GPD), pRS316GPDATP7Awt, pRS316GPDATP7ADex3ex4, pRS316GPDATP7AD1460,
pRS316GPDATP7AD1474, and pRS316GPDATP7AD1460,M475L. The wild-type strain 7 was transformed with EV. The transformed colonies were
cultured as described in the “Material and Methods” section. At optical density , an aliquot of 5 ml was streaked on platesOD p 0.1600
with iron-limited medium (A and D). Rescue of the Dccc2 yeast can also be accomplished by addition of either a high concentration
of copper (B and E) or iron (C and F) to the iron-limited medium.32,55 Plates were photographed after 4 d at 30C or 37C, as indicated.
Schematic illustration of the plates is shown.
speech.24 A reduced amount of endogenously synthesized
ATP7ADex3ex4 proteins could explain the lack of full com-
plementation. From previous studies, it has been shown
that, even when optimal conditions for reinitiation are
present, the degree of reinitiation is not 100%.39 Similarly,
we found a reduced in vitro reinitiation level, using the
ATP7ADex3ex4 cDNA sequence as template, compared with
the normal initiation level obtained using ATP7Awt cDNA
as template. The lack of detection of the endogenous
ATP7ADex3ex4 proteins by western blotting and the faint
IF signal in the major part of the cells support this
suggestion.
Another contributing factor could be that the region
containing CBS1–CBS4, indeed, has an important func-
tion in maintaining normal copper homeostasis in hu-
mans—a function that was not assessed here. For both
ATP7A and ATP7B, an interaction between the copper
chaperone, Atox1, and CBS1–CBS4 has been demon-
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Figure 10. Complementation efﬁciency of N-terminal–truncated
Menkes proteins synthesized in Dccc2 yeast. The growth in iron-
limited medium of wild-type strain 7 harboring pRS316GPD (EV)
( ) and of Dccc2 strain 8 harboring pRS316GPDATP7Awtnp 5
( ), pRS316GPDATP7ADex3ex4 ( ), pRS316GPDATP7AD1460np 4 np 3
( ), pRS316GPDATP7AD1474 ( ), andnp 3 np 3
pRS316GPDATP7AD1460,M475L ( ) was determined by OD600 mea-np 3
surements. OD600 (log scale) was plotted in comparison with time,
and, in accordance with the equation describing exponential
growth ( ), the doubling time was calculated as log2/logb.∗ xYp a b
SDs are shown.
strated.9,10,12 CBS2 and CBS4 have been identiﬁed as im-
portant sites in ATP7B for this interaction.11,12 It was pro-
posed that binding of copper to CBS2 works as a switch,
allowing subsequent loading of other sites.11
The diffuse localization pattern observed for the en-
dogenous ATP7ADex3ex4 proteins, especially in the presence
of low concentration of BCS, is similar to the ATP7A lo-
calization pattern in Atox1/ cells.49 Consistent with the
proposed role for Atox1 in copper delivery to the secretory
pathway, amarked increase in intracellular copper content
secondary to impaired copper efﬂux was observed in
Atox1/ cells. We speculate that copper efﬂux, in both
cases, is hampered because of a lack of interactionbetween
ATP7A and Atox1. Several disease-causing mutations in
ATP7B have been shown to interrupt the interaction be-
tween the ATP7B protein and Atox1,50 stressing the im-
portance of this interaction for copper homeostasis.
The Biochemical Phenotype of a Patient with MD and
Efﬁcacy of Copper Therapy
The treatment of MD involves copper replacement ther-
apy, where parenteral injections of copper histidinebypass
the intestinal blockage of dietary copper absorption, rais-
ing the circulating copper levels. Moreover, copper
crossing the blood-brain barrier is required to prevent the
classical neurological symptoms in patients with MD. It
has been shown elsewhere that the efﬁcacy of copper ther-
apy in patients with MD depends on the presence of re-
sidual ATP7A protein function.51 Patients with MD with
truncated and/or mislocated, but partially functional,
ATP7A proteins have been copper treated with success.52–
54 These results and the present case highlight the impor-
tance of investigating the biochemical phenotype of a pa-
tient to provide an estimation of copper-therapy success,
even though the genotype predicts a null mutation.
Conclusion
Reinitiation of NMD-resistant transcripts, combined with
a PTC located close to the initiation codon, might be sus-
pected in patients with less-severe symptoms of any type
of genetic disease. In the present case, a partial activity of
a truncated Menkes protein probably contributed to a less-
severe phenotype. The correlation between NMD and
reinitiation has previously been studied entirely with the
use of minigene transfection, where mutations were in-
troduced by site-directed mutagenesis. To our knowledge,
this is the ﬁrst direct demonstration of abrogation toNMD
combined with translation reinitiation of an endogenous
transcript.
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